4Q Revenues: $2.0 billion (+39%)
4Q Earnings: $457.3 million (+57%)
FY Revenues: $6.9 billion (+26%)
FY Earnings: $1.9 billion (+35%)
Comments: Growth in the quarter and FY were driven by sales of new multiple sclerosis drug, Tecfidera, with sales of $398 million in the quarter and $876 million for the year, and TYSABRI revenues, up 45% to $427 million in the quarter, and up 34% for the year to $1.5 billion, as a result of recording 100% of revenues after gaining full rights. AVONEX revenues were flat in the quarter at $751 million and up 3% for the year to $3.0 billion. Royalty revenues were $61 million in the quarter, up 9%, and $186 million for the year, up 10%.